Clinical Trials Directory

Trials / Unknown

UnknownNCT04975477

CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)

CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)

Status
Unknown
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.

Detailed description

Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study initialed and enrolled by Chinese Portal Hypertension Alliance (CHESS) aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.

Conditions

Interventions

TypeNameDescription
PROCEDUREEsophagogasrtoduodendoscopy and liver stiffnessTime frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
PROCEDUREhepatic venous pressure gradientA method was used to evaluate portal pressure.

Timeline

Start date
2021-07-16
Primary completion
2021-08-16
Completion
2021-08-16
First posted
2021-07-23
Last updated
2021-07-23

Locations

7 sites across 5 countries: China, Egypt, India, Japan, South Korea

Source: ClinicalTrials.gov record NCT04975477. Inclusion in this directory is not an endorsement.